The Minister of Health has seized the High Authority of Health (HAS) to allow all volunteers who wish to be vaccinated with the AstraZeneca serum, for the moment reserved for over 55s in France due to rare cases thrombosis. 

DECRYPTION

It is no longer injected to people under 55 in France, due to rare cases of thrombosis.

But could the AstraZeneca vaccine against Covid-19 soon be given to all those who, aware of this minimal risk, volunteer?

The Minister of Health Olivier Véran seized the High Authority of Health (HAS) in this direction, advancing the hypothesis that the French who wish it can sign a discharge.

Proof that the government does not want to release this vaccine, which is the subject of real mistrust. 

>> LIVE

- Covid-19: follow the evolution of the situation Wednesday, May 5

"It is to relieve the State of its responsibilities"

The fear is felt in the figures: for a few days, there are only 27,000 daily injections with AstraZeneca, against 75,000 two weeks ago.

A reluctance that falls at the worst of times, since France has just received a stock of two million doses - reason why the executive is looking for new ways to sell them. 

"We are really very surprised that the government offers patients to sign a waiver," comments at the microphone of Europe 1 Jean-Paul Hamon, honorary president of the Federation of Doctors of France.

"Because in fact, it is to release the State of its responsibilities", estimates it.

"I would be surprised if this proposal goes through."

CORONAVIRUS ESSENTIALS

 > How summer festivals adapt to be able to be held in the best conditions

> Still very much in the minority in France, why is the Brazilian variant so worrying?

> Covid-19: should we be concerned about vaccines created with adenovirus?

> In one year, the Covid-19 has destroyed 100 million tourism-related jobs

> How the pandemic reminded Europe of the notion of border

According to our information, the High Authority for Health will not comment on this possibility of discharge for patients.

But she could perhaps expand vaccination to those under 55, provided it is backed by solid scientific data.

If the HAS were to go in this direction, the idea would also be to inform patients more about the risks, however small, of the AstraZeneca vaccine.